Followup of 312 randomised and 108 unrandomised patients with primary biliary cirrhosis, a rare autoimmune liver disease, at Mayo Clinic.

datasets

survival analysis: descriptive statistics, two-sample
  tests, parametric accelerated failure models, Cox model. Delayed entry
  (truncation) allowed for all models; interval censoring for parametric
  models.

Thomas Lumley

survival

Survival analysis, including penalised likelihood.

pbc function

<tabular>ll</tabular>{
	age:	in yearsalb:	serum albuminalkphos:	alkaline phosphotaseascites:	presence of ascitesbili:	serum bilirunbinchol:	serum cholesteroledema:	presence of edemaedtrt:	0 no edema, 0.5 untreated or successfully treated	1 unsuccessfully treated edemahepmeg:	enlarged livertime: 	survival timeplatelet:	platelet countprotime:	standardised blood clotting timesex:	1=malesgot:	liver enzyme (now called AST)spiders:	blood vessel malformations in the skinstage:	histologic stage of disease (needs biopsy)status:	censoring statustrt:	1/2/-9 for control, treatment, not randomisedtrig:	triglyceridescopper:	urine copper}

format

Fleming TR, Harrington DP. "Counting Processes and Survival Analysis" Wiley:New York

pbc: Mayo Clinic Primary Biliary Cirrhosis Data

Description

Usage

Arguments

format

source